FDA delivers inspection results to Able Labs

Able Laboratories of Cranbury, New Jersey, received a list of "inspectional observations" from the FDA in connection to its product recall announcement and suspension of manufacturing operations. The tersely written inspection notice was announced on Friday, the same day that Able's interim CEO -- Robert G. Mauro -- resigned from his post. The generic drug maker says that it cannot be certain when or if operations will resume.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.